PriceSensitive

Kontrol (NEO:KNR) reports funding to accelerate development of real-time viral testing technology

Health Care, Technology
NEO:KNR
13 July 2022 16:30 (EDT)

Kontrol Technologies’ (KNR) operating subsidiary CEM Specialties is receiving advisory services and funding of up to $300,000.

The National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) funding supports a research and development project to accelerate its new wastewater testing technology – the Kontrol BioWater analyzer for detecting viruses, including COVID-19.

Kontrol BioWater technology will be designed with the goal of being the first real-time, in the cloud, detection technology for virus in wastewater.

The current process for collecting wastewater sampling involves onsite technicians transporting samples to a laboratory and undertaking a separate analysis of the wastewater.

This process is time-consuming and can take several days to complete. The Kontrol BioWater analyzer intends to advance sampling automation for faster, onsite detection, which can potentially accelerate a response plan.

Company CEO Paul Ghezzi, commented,

“We are pleased to continue to add to our growing technology platform and intellectual property as we advance the Kontrol BioWater to the next stage of its development.”

Gary Saunders, President of Kontrol BioCloud, added,

“Early viral detection is in its infancy, and we continue to build our BioCloud technology which will now include Kontrol BioWater.”

According to the company, it is not making any express or implied claims that its product can eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus).

Kontrol Technologies Corp. (KNR) is down 20.13 per cent, trading at $1.19 per share at close-of-day trading.

Related News